This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitt, B. Search for Related Content PubMed PubMed Citation Articles by Pitt, B.

(Circulation. 1998;98:1987-1989.)
© 1998 American Heart Association, Inc.

Editorial

Regression of Left Ventricular Hypertrophy in Patients With Hypertension

Blockade of the Renin-Angiotensin-Aldosterone System

Bertram Pitt, MD

From the Cardiology Division, University of Michigan Medical Center, Ann Arbor.

Correspondence to Bertram Pitt, MD, Cardiology Division, University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0366.

Key Words: Editorials • hypertrophy • hypertension

Left ventricular hypertrophy in patients with hypertension is of importance because of its association with an increase in the incidence of heart failure and other cardiovascular events, such as myocardial infarction and sudden cardiac death. Not all antihypertensive agents, however, have been suggested to be equally effective in causing regression of left ventricular hypertrophy or preventing its progression.¹ Although several classes of antihypertensive agents are effective in causing regression of ventricular hypertrophy, it is uncertain whether all strategies are equally effective and, more importantly, whether strategies equally effective in causing regression of ventricular hypertrophy will be equally effective in preventing the consequences of ventricular hypertrophy, such as myocardial infarction and sudden cardiac death.

The mechanism of ventricular hypertrophy in patients with hypertension is as yet uncertain; however, activation of the renin-angiotensin-aldosterone system (RAAS) as a result of myocardial stretch and other factors is recognized as playing an important role. Angiotensin II has been shown to stimulate various growth factors, cytokines, fibroblast activity, myocyte hypertrophy, and myocardial fibrosis. Strategies to prevent activation of the RAAS and/or its effects would therefore appear attractive in preventing ventricular hypertrophy and its consequences in patients with hypertension.

ACE inhibitors have been shown to cause a reduction in myocardial cytokines, growth factors, oxygen free radical production, collagen formation, and myocyte growth. They increase nitric oxide release and reduce morbidity, ischemic events, and mortality in patients with heart failure, including those with a history of hypertension. A meta-analysis of all antihypertensive agents has suggested that ACE inhibitors . . . [Full Text of this Article]

This article has been cited by other articles:

				R. S. Velagaleti, P. Gona, D. Levy, J. Aragam, M. G. Larson, G. H. Tofler, W. Lieb, T. J. Wang, E. J. Benjamin, and R. S. Vasan Relations of Biomarkers Representing Distinct Biological Pathways to Left Ventricular Geometry Circulation, November 25, 2008; 118(22): 2252 - 2258. [Abstract] [Full Text] [PDF]

				B. L. Metcalfe, M. J. Huentelman, L. D. Parilak, D. G. Taylor, M. J. Katovich, H. J. Knot, C. Sumners, and M. K. Raizada Prevention of Cardiac Hypertrophy by Angiotensin II Type-2 Receptor Gene Transfer Hypertension, June 1, 2004; 43(6): 1233 - 1238. [Abstract] [Full Text] [PDF]

				T. Walther, A. Schubert, V. Falk, C. Binner, C. Walther, N. Doll, A. Fabricius, S. Dhein, J. Gummert, and F. W. Mohr Left Ventricular Reverse Remodeling After Surgical Therapy for Aortic Stenosis: Correlation to Renin-Angiotensin System Gene Expression Circulation, September 24, 2002; 106(12_suppl_1): I-23 - I-26. [Abstract] [Full Text] [PDF]

				M.H. Yacoub A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery Eur. Heart J., April 1, 2001; 22(7): 534 - 540. [PDF]

				G.Y.H Lip, D.C Felmeden, F.L Li-Saw-Hee, and D.G Beevers Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur. Heart J., October 2, 2000; 21(20): 1653 - 1665. [PDF]

				A. Gurlek, E. Tutar, E. Akcil, I. Dincer, C. Erol, P. A. Kocaturk, and D. Oral The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy Eur J Heart Fail, June 1, 2000; 2(2): 189 - 193. [Abstract] [Full Text] [PDF]

				E. Cerbai, A. Crucitti, L. Sartiani, P. De Paoli, R. Pino, M. L. Rodriguez, G. Gensini, and A. Mugelli Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes Cardiovasc Res, January 14, 2000; 45(2): 388 - 396. [Abstract] [Full Text] [PDF]

				M. K. Raizada, M. J. Katovich, H. Wang, K. H. Berecek, and C. H. Gelband Is antisense gene therapy a step in the right direction in the control of hypertension? Am J Physiol Heart Circ Physiol, August 1, 1999; 277(2): H423 - H432. [Full Text] [PDF]